Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies

Neurology

Volumn 59, Issue 12 SUPPL. 6, 2002, Pages

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN;

ACUTE DISEASE; ALOPECIA; ANAPHYLAXIS; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ASEPTIC MENINGITIS; BLOOD VISCOSITY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CRYOGLOBULINEMIA; DEMYELINATION; DRUG EFFECT; DRUG MECHANISM; FATIGUE; FEVER; HEADACHE; HEMOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGAMMAGLOBULINEMIA; HYPONATREMIA; IMMUNOMODULATION; KIDNEY INJURY; KIDNEY TUBULE NECROSIS; MEDIATOR RELEASE; MIGRAINE; NAUSEA; PLASMAPHERESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION;

EID: 0037168786     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.59.12_suppl_6.s13     Document Type: Review

References (79)

1. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
2. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-116.
3. Dalakas MC. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med 1997;126:721-730.
4. Dalakas MC, ed. The use of intravenous immunoglobulin for neurologic diseases. Neurology 51(suppl 5):1998.
5. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle Nerve 1999;22:1479-1497.
6. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: An idiotype-anti-idiotype complex. Mol Immunol 1988;25:41-48.
7. Varela F, Andersson A, Dietrich G, et al. The population dynamics of antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 1991;88:5917-5921.
8. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990;144:1387-1392.
9. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85:620-629.
10. Kaveri S, Prasad N, Vassilev T, et al. Modulation of autoimmune responses by intravenous immunoglobulin. Mult Scler 1997;3:121-128.
11. Kazatchkine MD, Dietrich G, Hurez V, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev 1994;139:79-107.
12. Krause I, Blank M, Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIg preparations: In vivo study in naïve mice. J Clin Immunol 1998;18:52-60.
13. Lopez PH, Irazoqui FJ, Nores GA. Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies. J Neuroimmunol 2000;105:179-183.
14. Terryberry JW, Shoenfeld Y, Sherer Y, et al. Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations. Immunol Invest 2000;29:337-347.
15. Malik U, Oleksowicz L, Latov N, Cardo LJ. Intravenous γ-globulin inhibits binding of anti-GMI to its target antigen. Ann Neurol 1996;39:136-139.
16. Yuki N, Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci 1996;139:160-162.
17. Dalakas MC. Blockade of blocking antibodies in Guillain-Barré syndromes: "Unblocking" the mystery of action of IVIg. Ann Neurol 2002;51:667-669.
18. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 2002;51:673-680.
19. Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. Acute axonal Guillian Barré syndrome with IgG antibodies against motor axons following parenteral injection of gangliosides. Ann Neurol 1995;38:218-224.
20. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795.
21. Diegel M, Rankin B, Bolen J, Dubois P, Kiener P. Cross linking of Fc receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem 1994;269:11409-11416.
22. Uher F, Dickler HB. Cooperativity between B-lymphocytes membrane molecules: Independent ligand occupancy and crosslinking of antigen receptors and Fc gamma receptors down-regulates B lymphocyte function. J Immunol 1986;137:3124-3129.
23. Ghetic V, Ward ES. FcRn: The MHC Class I-related receptor that is more than an IgG transporter. Immunol Today 1997;18:592-598.
24. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-228.
25. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
26. Ankrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIg) in vivo down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999;115:136-143.
27. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993;92:2533-2539.
28. Leon-Monzon M, Dalakas MC. Interleukin-1 (IL-1) is toxic to human muscle. Neurology 1994;44(suppl):132. Abstract.
29. Dalakas MC, IIIa, I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
30. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor β. Lancet 1998;351:184-185.
31. Sharief MK, Ingram DA, Swash M, Thompson EJ. IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 1999;52:1833-1838.
32. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998;121:159-166.
33. Senzaki H, Masutani S, Kobayashi J, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 2001;104:860-863.
34. Kieseier BC, Tani M, Mahad D, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: A central role for IP-10. Brain 2002;125:823-834.
35. Damås JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure - Modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001;38:187-193.
36. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanisms of therapeutic effect of high-dose intravenous immunoglobulin. J Clin Invest 1989;84:1974-1981.
37. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991;325:1487-1498.
38. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
39. Dalakas MC. Clinical relevance of IVIg in the modulation of the complement-mediated tissue damage: Implications in dermatomyositis, Guillain Barré syndrome and myasthenia gravis. In: Kazatchkine M, Morel D, eds. Intravenous Immunoglobulin Research and Therapy. London: Parthenon Publishing, 1996:89-93.
40. Basta M, Illa I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol 1996;71:227-229.
41. Dalakas MC, Engel WK. Immunoglobulin deposits in chronic relapsing polyneuropathles. Arch Neurol 1980;37:637-640.
42. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-644.
43. Dalakas MC. Mechanism of action of intravenous immunolobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998;51(suppl 5):2-8.
44. Dalakas MC. Autoimmune peripheral neuropathies. In: Rich RR, ed. Clinical Immunology. St. Louis: Mosby Year Book, 1995:1377-1394.
45. Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 1980;66:773-781.
46. Kurlander RJ, Hall J. Comparison of intravenous gammaglobulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986;77:2010-2018.
47. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIg mediated through the inhibitory Fc receptor. Science 2001;291:484-486.
48. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T cell receptor Vβ chain. Proc Natl Acad Sci USA 1992;89:3325-3329.
49. Leung DY, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987;79:468-472.
50. Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: Present and future prospects. Ann Neurol 1995;37(suppl 1):2-13.
51. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997;20:1102-1107.
52. Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: Specific effect on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994;71:309-314.
53. Blasczyk R, Westhoff V, Grosse-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790.
54. Kaveri S, Vassilev T, Hurex V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:868-869.
55. Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in chronic inflammatory demyelinating polyneuropathy. Brain 2000;123:1660-1666.
56. Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith KJ, Hughes RA. Human immunoglobulin ameliorates rat experimental allergic neuritis. Brain 1997;120:1533-1540.
57. van Engelson BG, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994;57(suppl):65-68.
58. Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998;161:3781-3790.
59. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
60. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994;121:259-262.
61. Newburger JW, Takahashi M, Berser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-1639.
62. Kanra G, Uzon A, Vajsar J, Castagna L, Secmeer G, Topaloglu H. Intravenous immunoglobulin treatment in children with Guillain Barré syndrome. Eur J Pediatr Neurol 1997;1:7-12.
63. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-449.
64. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 1994;44:223-226.
65. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-258.
66. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1181.
67. Hague RA, Eden DB, Yap PL, Mok JYO, Rae P. Hyperviscosity in HIV infected children: A potential hazard during intravenous immunoglobulin therapy. Blut 1990;61:66-67.
68. Voltz RV, Rosen F, Yousry T, Beck J, Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a GBS patient treated with IV immunoglobulin. Neurology 1996;46:250-251.
69. Constantinescu CS, Chang AP, McClusky LF. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med 1993;329:583-584.
70. Dalakas MC. Aseptic meningitis and intravenous immunoglobulin. Ann Intern Med 1995;122:316-317.
71. Dalakas MC. Meningitis and skin reactions after intravenous immunoglobulin therapy. Ann Intern Med 1997;127:1130.
72. Chan-Lam D, Fitzsimmons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet 1982;1:1436.
73. Boom BW, Brand A, Bavinek JB, et al. Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose immunoglobulin intravenously. Arch Dermatol 1988;124:1550-1553.
74. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med 1986;314:560-564.
75. Björkander J, Hammarström L, Smith E, Buckley RH, Cunningham-Rundles C, Hanson LA. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987;7:8-15.
76. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327:1032-1033.
77. Asham N, Palmer BF, Wheeler D, et al. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154:1985-1987.
78. Asham N. Intravenous immunoglobulin induced-nephropathy: A complication of IVIg therapy. J Nephrol 1998;11:157-161.
79. Blick KE, Liles SM. Principles of Clinical Chemistry. New York: John Wiley & Sons, 1985.